+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neurofibromatosis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Recent Developments

  • PDF Icon

    Report

  • 91 Pages
  • May 2018
  • Region: Global
  • Knowledge Sourcing Intelligence LLP
  • ID: 4542620
Neurofibromatosis Pipeline Analysis 2018 - Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

Neurofibromatosis Pipeline Analysis report covers 15 drugs currently in different phases of development. Neurofibromatosis is a genetic disorder characterised by formation of tumors on nerve tissue. There are 3 main types of neurofibromatosis: Neurofibromatosis type 1 (NF1), Neurofibromatosis type 2 (NF2) and Schwannomatosis. Neurofibromatosis type 1 (NF1) is the most common type of neurofibromatosis followed by NF2 and Schwannomatosis. Symptoms of the disease includes presence of café-au-lait spots, Lisch nodules, optic glioma, skeletal defects and freckling under the arms or in groin.

The report provides Neurofibromatosis treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Betta Pharmaceuticals Co.,Ltd., E.Z. BioXcel, Lixte Biotechnology Holdings, Inc. and Recursion Pharmaceuticals, Inc. among others.

Scope:

By Company:

By Phase:
  • NDA filed

  • Phase III

  • Phase II

  • Phase I

  • Pre-clinical

  • Discovery

  • By Molecule Type

  • Small molecules

  • Biologics

  • Peptides or Small proteins


By Region:
  • North America

  • South America

  • Europe

  • Middle East and Africa

  • Asia Pacific


By Route of Administration:
  • IV

  • IM

  • S/C

  • Oral

  • Intratumoral

Table of Contents

1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region

2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology

3. Executive Summary

4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities

5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profile
  • Drug Name

  • Generic Name

  • Synonyms

  • Company

  • Collaborator

  • Route of administration

  • Target

  • Mechanism of Action

  • Technology

  • Molecule type

  • CAS Number

  • Weight

  • Chemical Formula

  • IUPAC name

  • ATC code

5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region

6. Company profiling
6.1. Alexion
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. AstraZeneca
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Betta Pharmaceuticals Co.,Ltd.
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Celldex Therapeutics Inc
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Daewon Pharmaceutical Co., Ltd.
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. E.Z. BioXcel
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. Genentech, Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT
6.8. GL Pharm Tech Corporation
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Lixte Biotechnology Holdings, Inc.
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Novartis
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT
6.11. Plex Pharmaceuticals
6.11.1. Introduction
6.11.2. Financials
6.11.3. Products and Services
6.11.4. SWOT
6.12. Recursion Pharmaceuticals, Inc.
6.12.1. Introduction
6.12.2. Financials
6.12.3. Products and Services
6.12.4. SWOT
6.13. Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd
6.13.1. Introduction
6.13.2. Financials
6.13.3. Products and Services
6.13.4. SWOT
6.14. Synta Pharmaceuticals Corp.
6.14.1. Introduction
6.14.2. Financials
6.14.3. Products and Services
6.14.4. SWOT
6.15. The Butte Lab
6.15.1. Introduction
6.15.2. Financials
6.15.3. Products and Services
6.15.4. SWOT

List of Tables
List of Figures

Companies Mentioned

  • Alexion

  • AstraZeneca

  • Betta Pharmaceuticals Co.,Ltd.

  • Celldex Therapeutics Inc

  • Daewon Pharmaceutical Co., Ltd.

  • E.Z. BioXcel

  • Genentech, Inc.

  • GL Pharm Tech Corporation

  • Lixte Biotechnology Holdings, Inc.

  • Novartis

  • Plex Pharmaceuticals

  • Recursion Pharmaceuticals, Inc.

  • Shandong Simcere-Medgenn Bio-pharmaceutical Co., Ltd

  • Synta Pharmaceuticals Corp.

  • The Butte Lab

Methodology

Loading
LOADING...